Tech Company Inital Public Offerings

Kronos Bio IPO

Kronos Bio, based in San Mateo, debuted as a public company on 10/8/2020.

Transaction Overview

Company Name
Announced On
10/8/2020
Transaction Type
IPO
Amount
$250,800,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:approximately $80.0 million to $90.0 million to fund our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC in AML patients with NPM1 mutations, which includes a $29.0 million milestone payment by us to Gilead upon the initiation of this trial;approximately $20.0 million to $30.0 million to fund our planned Phase 1/2 clinical trial of KB-0742 for the treatment of advanced solid tumors; andthe remainder for additional development activities for our SYK and CDK9 programs, continued discovery and preclinical development of additional product candidates, as well as headcount costs, working capital and other general corporate purposes.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1300 So. El Camino Real 300
San Mateo, CA 94402
USA
Phone
Undisclosed
Email Address
Overview
Kronos Bio (Nasdaq: KRON) is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
Profile
Kronos Bio LinkedIn Company Profile
Social Media
Kronos Bio Company Twitter Account
Company News
Kronos Bio News
Facebook
Kronos Bio on Facebook
YouTube
Kronos Bio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Norbert Bischofberger
  Norbert Bischofberger LinkedIn Profile  Norbert Bischofberger Twitter Account  Norbert Bischofberger News  Norbert Bischofberger on Facebook
Chief Financial Officer
Yasir Al-Wakeel
  Yasir Al-Wakeel LinkedIn Profile  Yasir Al-Wakeel Twitter Account  Yasir Al-Wakeel News  Yasir Al-Wakeel on Facebook
Chief Marketing Officer
Jorge DiMartino
  Jorge DiMartino LinkedIn Profile  Jorge DiMartino Twitter Account  Jorge DiMartino News  Jorge DiMartino on Facebook
Chief Operating Officer
Barbara Kosacz
  Barbara Kosacz LinkedIn Profile  Barbara Kosacz Twitter Account  Barbara Kosacz News  Barbara Kosacz on Facebook
Chief Scientific Officer
Christopher Dinsmore
  Christopher Dinsmore LinkedIn Profile  Christopher Dinsmore Twitter Account  Christopher Dinsmore News  Christopher Dinsmore on Facebook
Vice President
Christopher Lee
  Christopher Lee LinkedIn Profile  Christopher Lee Twitter Account  Christopher Lee News  Christopher Lee on Facebook
Vice President
Charles Lin
  Charles Lin LinkedIn Profile  Charles Lin Twitter Account  Charles Lin News  Charles Lin on Facebook
Vice President
Douglas Saffran
  Douglas Saffran LinkedIn Profile  Douglas Saffran Twitter Account  Douglas Saffran News  Douglas Saffran on Facebook
Vice President
Wes Trotter
  Wes Trotter LinkedIn Profile  Wes Trotter Twitter Account  Wes Trotter News  Wes Trotter on Facebook
VP - Bus. Development
Philip Gutry
  Philip Gutry LinkedIn Profile  Philip Gutry Twitter Account  Philip Gutry News  Philip Gutry on Facebook
VP - Operations
Zung To
  Zung To LinkedIn Profile  Zung To Twitter Account  Zung To News  Zung To on Facebook
VP - Regulatory Affairs
Jennifer Nicholson
  Jennifer Nicholson LinkedIn Profile  Jennifer Nicholson Twitter Account  Jennifer Nicholson News  Jennifer Nicholson on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/8/2020: Avail Medsystems venture capital transaction
Next: 10/8/2020: Cerebral venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary